|
05-NOV-2009
Subject PRO/AH/EDR VACCINIA, HUMAN, ORAL RABIES VACCINE - USA: (PENNSYLVANIA) "On day 12, in an attempt to reduce viral replication and prevent progressive vaccinia, a 2nd 6000 IU/kg dose of VIGIV was administered along with the investigational antiviral agent ST-246 (SIGA Technologies, Corvalis, Oregon). The ST-246 was administered orally for 14 days after a compassionate use authorization was approved by the Food and Drug Administration. On day 13, the patient began receiving phased reintroduction of her immunosuppressive medications. She was discharged on day 19. By day 28, all scabs from her lesions had separated and her underlying inflammatory bowel disease condition was stable. The patient remained Orthopoxvirus IgM negative throughout her illness." http://www.promedmail.org/pls/otn/f?p=24... Rating :
 (1 Rating) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|